Search

Scientists at Bristol Myers Squibb's Devens facility are utilizing artificial intelligence to monitor critical variables in the production of disease-fighting proteins, enhancing drug manufacturing efficiency by 40% and tackling shortages, while the company faces tough competition from China's rapidly advancing biotech sector and implements cost-cutting measures in light of patent expirations and the potential impact of AI on jobs in the industry. #ArtificialIntelligence #PharmaceuticalInnovation #Biotechnology #US #CN #TH

In a Bristol Myers Squibb lab near Boston, scientists are utilizing artificial intelligence to optimize the production of genetically engineered proteins for disease treatment by precisely monitoring key variables in the biomanufacturing process, resulting in a 40% increase in drug production and addressing challenges related to drug shortages, while the company also faces the looming impact of cost-cutting measures and potential job losses due to automation advancements. #ArtificialIntelligence #PharmaceuticalInnovation #DrugDiscovery #US #CN #TH